Study of Tesetaxel in Japanese Patients With Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

September 30, 2012

Conditions
Advanced Solid Tumors
Interventions
DRUG

Tesetaxel

The starting dose for the first 3 patients treated will be 24 mg/m2. In the absence of dose-limiting toxicity, the dose will be increased by 3 mg/m2 for the next group of 3 patients treated. Interpatient dose escalation will continue in this manner to 27 and 31 mg/m2 until the maximum tolerated dose or the maximum dose allowed per protocol (31 mg/m2) is reached and 6 patients are treated at this dose.

Trial Locations (1)

589-8511

RECRUITING

Kinki University School of Medicine, Osaka-fu

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genta Incorporated

INDUSTRY

NCT01337310 - Study of Tesetaxel in Japanese Patients With Solid Tumors | Biotech Hunter | Biotech Hunter